As expected, the HRs of all-cause mortality increased in relation to advanced tumor stage [HR for stage IV versus stage 0 or I: 12.60, 95% confidence interval (95% CI): 6.23–25.30], higher grade (HR for grade III/IV versus grade I: 2.18, 95% CI: 1.18–4.04), and negative hormone receptor status (HR for ER− and PR− versus ER+ or PR+: 2.18, 95% CI: 1.45–3.28). Here, ESR1 is linked to neoplasm.